S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

REGENXBIO Stock Forecast, Price & News

-0.50 (-1.97%)
(As of 01/21/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
456,946 shs
Average Volume
412,146 shs
Market Capitalization
$1.07 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive RGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.



REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors; and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$154.57 million
Book Value
$10.10 per share


Net Income
$-111.25 million
Net Margins
Pretax Margin




Free Float
Market Cap
$1.07 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.23 out of 5 stars

Medical Sector

362nd out of 1,419 stocks

Biological Products, Except Diagnostic Industry

52nd out of 206 stocks

Analyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -

REGENXBIO (NASDAQ:RGNX) Frequently Asked Questions

Is REGENXBIO a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REGENXBIO stock.
View analyst ratings for REGENXBIO
or view top-rated stocks.

How has REGENXBIO's stock been impacted by COVID-19 (Coronavirus)?

REGENXBIO's stock was trading at $32.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RGNX stock has decreased by 24.3% and is now trading at $24.91.
View which stocks have been most impacted by COVID-19

When is REGENXBIO's next earnings date?

REGENXBIO is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for REGENXBIO

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) posted its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($1.37) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.87) by $0.50. The biotechnology company had revenue of $30.77 million for the quarter, compared to analysts' expectations of $49.35 million. REGENXBIO had a negative net margin of 228.08% and a negative trailing twelve-month return on equity of 44.70%. During the same period in the previous year, the company posted $0.23 EPS.
View REGENXBIO's earnings history

What price target have analysts set for RGNX?

7 brokerages have issued twelve-month target prices for REGENXBIO's shares. Their forecasts range from $17.00 to $90.00. On average, they anticipate REGENXBIO's stock price to reach $54.00 in the next year. This suggests a possible upside of 116.8% from the stock's current price.
View analysts' price targets for REGENXBIO
or view top-rated stocks among Wall Street analysts.

Who are REGENXBIO's key executives?

REGENXBIO's management team includes the following people:
  • Kenneth T. Mills, President, Chief Executive Officer & Director
  • Curran M. Simpson, SVP, Chief Operations & Technology Officer
  • Vit Vasista, Chief Financial Officer & Senior Vice President
  • Olivier Danos, Chief Scientific Officer & Senior Vice President
  • Stephen Pakola, Chief Medical Officer & Senior Vice President

What is Ken Mills' approval rating as REGENXBIO's CEO?

3 employees have rated REGENXBIO CEO Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among REGENXBIO's employees.

What other stocks do shareholders of REGENXBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Square (SQ).

What is REGENXBIO's stock symbol?

REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."

Who are REGENXBIO's major shareholders?

REGENXBIO's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Liberty One Investment Management LLC (0.07%), State of Alaska Department of Revenue (0.06%) and Cutler Group LP (0.00%). Company insiders that own REGENXBIO stock include Allan M Fox, Curran Simpson, Kenneth T Mills, Kenneth T Mills, Patrick J Christmas, Steve Pakola, Vittal Vasista and WR Stephens, Iii 2012 Trust.
View institutional ownership trends for REGENXBIO

Which major investors are selling REGENXBIO stock?

RGNX stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP, and State of Alaska Department of Revenue. Company insiders that have sold REGENXBIO company stock in the last year include Allan M Fox, Kenneth T Mills, Steve Pakola, and WR Stephens, Iii 2012 Trust.
View insider buying and selling activity for REGENXBIO
or view top insider-selling stocks.

Which major investors are buying REGENXBIO stock?

RGNX stock was acquired by a variety of institutional investors in the last quarter, including Liberty One Investment Management LLC.
View insider buying and selling activity for REGENXBIO
or or view top insider-buying stocks.

How do I buy shares of REGENXBIO?

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is REGENXBIO's stock price today?

One share of RGNX stock can currently be purchased for approximately $24.91.

How much money does REGENXBIO make?

REGENXBIO has a market capitalization of $1.07 billion and generates $154.57 million in revenue each year. The biotechnology company earns $-111.25 million in net income (profit) each year or ($5.17) on an earnings per share basis.

How many employees does REGENXBIO have?

REGENXBIO employs 306 workers across the globe.

What is REGENXBIO's official website?

The official website for REGENXBIO is www.regenxbio.com.

Where are REGENXBIO's headquarters?

How can I contact REGENXBIO?

REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at (240) 552-8181 or via email at [email protected].

This page was last updated on 1/23/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.